Medtronic Canada announces commercial launch of Mazor X, the first dedicated robotic spinal surgery platform in Canada

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) a global leader in healthcare technology, today announced the commercial launch of the Mazor™ X System (herein referred to as Mazor) for robotic-guided spine surgery. The Mazor platform offers a fully integrated procedural solution for surgical planning, workflow, execution and confirmation, and is the first dedicated robotic assisted spine surgery platform being launched in Canada .

Mazor Spinal Robotic system (CNW Group/Medtronic Canada ULC)

The Mazor platform seamlessly incorporates existing StealthStation™ S8 surgical navigation capabilities into the Mazor Core Technology robotic-assisted surgery platform. Real-time image guidance, visualization and navigation are informed by interactive 3D planning and information systems to deliver workflow predictability and flexibility for procedures.

"The integration of navigation and robotic technologies into one platform is an exciting advancement in the field of spinal surgery," says Dr. Scott Paquette , orthopedic spine surgeon, and president of the Canadian Spine Society. "Mazor represents an incredible future of possibilities in spinal robotics, which I believe will greatly contribute to reduced risk for patients."

The three-dimensional Mazor platform allows surgeons to quickly visualize anatomy and spinal structures in relation to one another. This provides surgeons with access to plan and simulate spinal cages and screws in advance, with the goal of increasing efficiencies and surgical precision.

The best-in-class Midas Rex™ MR8 Electric High Speed Drill Systems are fully integrated throughout the Mazor system, enabling improved trajectory precision starting with pilot hole creation and offering attachments and dissecting tools designed to drill with accuracy at speeds up to 75,000 rpm. Surgeons can now use navigated interbody features on the Mazor system to visualize disc prep and interbody placement during a robotic procedure.

"Mazor embodies a synergy between robotics and navigation, providing a rigorous degree of accuracy integrated throughout the surgical procedure, with the hope of producing more reliable outcomes," 1 says Peter Tomashewski , senior director, Neuro and Spine Surgery, within the Cranial & Spinal Technologies business at Medtronic Canada. "The addition of Mazor to our portfolio provides another transformative tool that elevates our value driven solutions for spinal care."

Learn more at medtronic.ca/mazor

About Medtronic Canada ULC
Bold thinking. Bolder actions. We are Medtronic. Proud to serve Canadian healthcare for over 50 years, Medtronic Canada ULC is headquartered in Brampton, Ontario , with regional offices in Montreal and Vancouver , and is a subsidiary of Medtronic plc. We are the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Our technologies and therapies address 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic Canada, visit www.Medtronic.ca and follow @MedtronicCA on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 Data on File.

Medtronic (CNW Group/Medtronic Canada ULC)

SOURCE Medtronic Canada ULC

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/October2021/25/c8783.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

  • New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon delivery
  • AVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies ("CRT") 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic ("PK") data on Virtue ® Sirolimus AngioInfusion Balloon ("SAB"), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×